Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to email their news releases to BioNJ.
August 6
NPS Pharmaceuticals Joins the Oley Foundation in Recognizing HPN Awareness Week, August 5-11
Celgene Announces Offering of Senior Unsecured Notes
August 3
Hospitals, Healthcare Providers to Benefit from a New Premier Agreement for Anti-Infection Site Disc Dressings
August 2
Celldex Therapeutics to Report Second Quarter 2012 Financial Results and Host Corporate 2012 Objectives Update Call
Cancer Genetics, Inc. Selected by Roche Servicios S.A. to Provide Services for the Diagnosis and Personalization of Oncology Treatment
August 1
Global Life Sciences Hiring Demand Increases 11.1% in Q2 2012
NPS Pharmaceuticals Reports Second Quarter 2012 Financial Results
July 31
Lexicon Pharmaceuticals Reports on Clinical Program Status and 2012 Second Quarter Results
July 30
Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting
Dendreon Announces Strategic Restructuring to Accelerate Path to Profitability and Future Growth
Dendreon Announces Second Quarter 2012 Results
Oncobiologics, Inc. Announces Strategic Partnership with XOMA Corporation to Utilize Fully Human Antibodies for Their Discovery Platform
NovaDel Reports Unaudited Financial Results for the Six Months Ended June 30, 2012
July 27
Merck Announces Second-Quarter 2012 Financial Results
NPS Pharmaceuticals to Report Second Quarter 2012 Financial Results
Neurotez, Inc. Announces Grant of U.S. Patent 8,227,408 Around Its Leptin Therapy for Alzheimer’s Disease
Bracco Diagnostics Receives U.S. FDA Approval for Expanded Labeling of MultiHance® (gadobenate dimeglumine) Injection in Magnetic Resonance Angiography
July 26
Celgene Reports Second Quarter 2012 Operating and Financial Results
Protalex, Inc. Findings from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active Rheumatoid Arthritis
Keynote Speakers Announced for Sixth Annual Pinsonault Managed Markets Summit
Bristol-Myers Squibb Foundation Marks World Hepatitis Day 2012 with New Grants Focused on Hepatitis B and Hepatitis C Patient Empowerment in China and India
Bristol-Myers Squibb Prices $2.0 Billion of Senior Notes
Unigene Provides Update Following Recent EMA Recommendation on Calcitonin-Containing Medicines
Merck Recognizes World Hepatitis Day with Partnerships and Grants to Support Global and U.S. Hepatitis C Communities
As Expected, Q2 2012 Business EPS1 Impacted by the Loss of Exclusivity of Plavix® and Avapro® in the U.S.
Gilead Sciences Announces Second Quarter 2012 Financial Results
July 25
Columbia Laboratories to Discuss Second Quarter 2012 Financial Results on August 8, 2012, Conference Call
Bard Announces Second Quarter Results
Bard Announces Enrollment Completion of First Ever IDE-Approved Drug-Coated Balloon Clinical Trial and Initiation of Large Continuation Registry Study
Bristol-Myers Squibb’s Second Quarter Highlighted by the Planned Strategic Acquisition of Amylin Pharmaceuticals and Important Clinical Data in Immuno-Oncology
The Medicines Company Reports Second Quarter and First Half 2012 Financial Results
Merck, Collaborators Publish Study Showing Potential for Eradication of Persistent HIV Virus in the Body
Sanofi Pasteur’s Dengue Vaccine Demonstrates Proof of Efficacy
July 24
Lexicon to Provide Second Quarter 2012 Financial Results
Karolinska Institutet and Immunomedics Develop New Anti-HIV Drug
ADMA Biologics Appoints Plasma Industry Leader Lawrence Guiheen to Board of Directors
Catalent Announces Commencement of Supply of Abilify® Orally Disintegrating Tablets to Otsuka Pharmaceutical Co., Ltd. and Extensive Investments to Its Zydis® Technology Capabilities in Swindon, UK
IMS Health to Issue Second-Quarter 2012 Financial Results on July 30, Conference Call for Note Holders Scheduled for August 2
Merck Announces Fourth-Quarter 2012 Dividend
Durata Therapeutics Closes Initial Public Offering
Gilead’s Once-Daily Single Tablet Regimen Complera® Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens
Gilead’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study
Gilead’s HIV Integrase Inhibitor Elvitegravir Dosed Once Daily as Effective as Twice-Daily Raltegravir Over Two Years of Therapy in Pivotal Phase 3 Study
July 23
Derma Sciences Announces Issuance of Two New U.S. Patents For DSC127
ADMA Biologics Appoints James Mond, M.D., Ph.D. as Chief Medical and Scientific Officer
Forest Laboratories and Almirall Announce FDA Approval of Tudorza™ Pressair™ for the Long-Term Maintenance Treatment of COPD
Lexicon to Provide Second Quarter 2012 Financial Results
Savient Pharmaceuticals Receives Favorable Decision in Tang Capital Litigation
Pfizer Announces Topline Results of First of Four Studies In Bapineuzumab Phase 3 Program
PTC Therapeutics Closes $30 Million Financing
July 22
ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 for up to 240 Weeks
July 19
Durata Therapeutics Prices Initial Public Offering
BRISK-FL Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Does Not Meet Overall Survival Primary Endpoint
July 18
Alliance Life Sciences Consulting Group and Adjility Consulting Announce Merger, Create Global Enterprise with Expanded Capabilities
July 17
Soligenix Announces $600,000 NIAID SBIR Grant Award Supporting Further Evaluation of OrbeShield™ as a Treatment for Acute Radiation Syndrome
Amicus Therapeutics and GlaxoSmithKline Expand Fabry Disease Collaboration
July 16
Celgene Corporation to Announce Second Quarter 2012 Results on July 26, 2012
July 13
Derma Sciences Acquires Global Long-Term Exclusive Rights to NIMBUS Technology from Quick-Med Technologies
Merck Highlights Data Presentations at the Alzheimer’s Association International Conference, 2012
Enzon Presents Pre-Clinical Data on Controlled Release of PEGylated Interferon-Beta-1b and PEGylated anti-TNF-a Antibody Fragment at the Controlled Release Society Annual Meeting
July 12
IMS Study Forecasts Rebound in Global Spending on Medicines, Reaching Nearly $1.2 Trillion By 2016
Apremilast Achieves Statistical Significance for the Primary Endpoint of the First Phase III Study (PALACE-1) in Patients with Psoriatic Arthritis
July 11
PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
Merck Announces Collaboration to Improve Maternal Health through Expanded Access to Family Planning
Medikly Expands KONNECT to Marketers; Redefines How Pharma Connects with Physicians
Cleveland Clinic Lou Ruvo Center for Brain Health and MedAvante Announce Alliance
Actinium Pharmaceuticals, Inc. Licenses Monoclonal Antibody from Fred Hutchinson Cancer Research Center
Update on Phase III Trial for Odanacatib, Merck’s Investigational Cat-K Inhibitor for Osteoporosis
The Medicines Company to Announce Second Quarter 2012 Financial Results on Wednesday, July 25, 2012
July 10
Advaxis to Present at the 2012 Southern California Investment Forum & the OneMedForum NY 2012 Conference
Blood Conservation Improves Outcomes
SOPHION and CREACELL Announce Successful Demonstration of the Performance of HEK-hKir2.1 Cells on QPatch HT
Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals, Inc.
CRI Lifetree Opens New Early Stage Research Facility
July 9
Lux Biosciences Completes Enrollment in Phase 3 Study of Non-infectious Uveitis Drug Candidate Luveniq
BioRx Acquires Coagulife Pharmacy
Advaxis Announces 2012 Annual Meeting of Stockholders
July 7
Interview: Simplifying Existing Procedure Eases Market Penetration for Photocure
July 6
Aegerion Pharmaceuticals Announces Participation at JMP Securities Healthcare Conference
July 5
Photocure Strengthens the Management Team
July 3
NPS Pharmaceuticals to Present at JMP Securities Healthcare Conference
July 2
Antares Pharma Appoints Jonathan S. Jaffe MD Vice President of Clinical Development
NPS Pharmaceuticals Announces Amended Royalty Agreement with Amgen
CorMedix: Granted Extension of NYSE Amex Listing
Bristol-Myers Squibb to Announce Results for Second Quarter 2012 on July 25
Amicus Therapeutics Announces Publication of BLISS Quantitative Histology Method in Archives of Pathology & Laboratory Medicine
The Medicines Company Expects Cangrelor Phase 3 Trial Enrollment Completion in 2012
June 29
Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals
June 28
Unigene’s Oral PTH Phase 2 Proof-of-Concept Data to Be Presented at Upcoming Scientific Conferences
FSS Announces CE Mark for its FlexStent® Iliac Self-Expanding Stent System
Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
June 27
Derma Sciences Announces Publication of DSC127 Phase 2 Trial Results in Wound Repair and Regeneration
Merck to Hold Second-Quarter 2012 Sales and Earnings Conference Call on July 27
Merck and AstraZeneca Agree to Amend Partnership
Lt. Governor Kim Guadagno Visits VaxInnate on Statewide Tour of Life Sciences Firms
PTC Therapeutics Initiates Open-Label Study for Ataluren in Patients with Nonsense Mutation Duchenne/Becker Muscular Dystrophy
June 26
NPS Pharmaceuticals Launches Educational Website on Hypoparathyroidism
Antares Pharma Announces Positive Results from VIBEX MTX Usability Study
Karen Bien, Pfizer, Elected to Board of Directors, SAFE-BioPharma Association
GenPath Diagnostics of BioReference Laboratories, Inc. Awarded 2012 Clinical Diagnostics Company of the Year Award by Frost & Sullivan
Sordoni Construction Helping to Build the Future of Medicine
Bristol-Myers Squibb Announces Dividend
Amicus Therapeutics Announces Positive Preliminary Results from Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy (ERT) Co-Administration Study for Pompe Disease
June 25
New Findings from REPLACE Study Support Potential of Natpara™ to Treat Adult Hypoparathyroidism
Ezose Sciences Announces Appointment of Chief Operating Officer
Lexicon Announces Positive Results of LX4211 Phase 2b Trial for Type 2 Diabetes
Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS® (apixaban)
June 22
International “I Plan On…” Survey from MSD Showed Gaps in Women’s Awareness of and Knowledge About the Range of Available Birth Control Options
Takeda Receives Positive CHMP Opinion for Teduglutide (Revestive®) for Patients with Short Bowel Syndrome
June 21
Celgene Provides Regulatory Update
June 20
MicroDose Therapeutx and Moerae Matrix Announce Collaboration to Develop Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis (IPF)
Bristol-Myers Squibb and Emory University Announce Partnership to Advance Clinical Development of Investigational Compounds
Merck Statement on CDC Advisory Committee on Immunization Practices’ Recommendation for Pneumococcal Vaccination in Immunocompromised Adults
Amicus Therapeutics Appoints Robert Essner to Board of Directors
June 19
BayBio: Ten U.S. High School Students Win Biotechnology Research Competition
Enzon Announces Data from Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference
June 18
Advaxis to Present at the 2012 BIO International Convention
Merck to Present at Wells Fargo Securities Research and Economics 2012 Health Care Conference
Geisinger and Merck to Collaborate on Multi-year Effort to Improve Patient Adherence, Engagement and Care Delivery
Sanofi Sponsors 2012 BIO International Convention, Jun 18 – 21, 2012, in Boston MA, US
Berkley Life Sciences Fills Coverage Void with Drug & Medical Device Shortage Coverage
NPS Pharmaceuticals Reports Natpara™ Phase 3 Results to be Presented at ENDO, the Annual Meeting of The Endocrine Society
Final Transition Milestone for Hexvix® Achieved
Enzon Announces Data from Phase I Study of PEG-SN38 in Pediatric Neuroblastoma and Other Solid Tumors Presented at 2012 Advances in Neuroblastoma Research Conference
June 15
Dr. Lex Van der Ploeg Has Been Elected to the Neurotez Inc. Board of Directors
Janssen Pharmaceutical Companies of Johnson & Johnson Sponsors 2012 BIO International Convention, Jun 18 – 21, 2012, in Boston MA, US
U.S. District Court Rules Against Merck in NASONEX® (mometasone furoate monohydrate) Patent Lawsuit
June 14
Advaxis to Present at the Inaugural Marcum MicroCap Conference on June 20th in NYC
STENTYS Starts Clinical Trial to Broaden Portfolio with New Drug-Eluting Stent
CorMedix Provides an Update on CE Marking Process for Neutrolin® in the EU
June 13
Ophthotech’s Novel Anti-PDGF Combination Agent Fovista™ Demonstrated Superior Efficacy over Lucentis® Monotherapy in Large Controlled Wet AMD Trial
Aegerion Pharmaceuticals Announces Participation at Wells Fargo Securities 2012 Healthcare Conference
Celgene Announces Additional $2.5 Billion Share Repurchase Program
Advaxis ADXS-PSA Construct Causes Significant Tumor Regression in Preclinical Prostate Cancer Study
CircuLite® to Present at Wells Fargo Securities Healthcare Conference
Immunomedics Reports Updated Results from Phase I Pretargeting Therapy Study in Colorectal Cancer
Immunomedics Develops Potential New Treatment Regimen for Non-Hodgkin Lymphoma
Bard Announces $500 Million Share Repurchase Authorization
Amicus Therapeutics Appoints Ted W. Love, M.D. to Board of Directors
June 12
VaxInnate Begins Phase I Clinical Trial to Evaluate H5N1 Vaccine Candidate for Pandemic Avian Flu
June 11
AcquiSci Receives Award from Hackensack University Medical Center to Research Company’s Patented Anti-Inflammatory d-OSAB™ Technology
Immunomedics Reports Development of a New Labeling Kit for Attaching Fluorine-18 to Peptides and Temperature-Sensitive Biomolecules, Including Antibodies
June 9
New Data Show Investigational Compound Dapagliflozin Demonstrated Significant Reductions in Blood Sugar Levels When Added to Sitagliptin in Adults with Type 2 Diabetes at 24 Weeks, with Results Maintained Over 48 Weeks
June 8
Government of Canada Awards CA$700,000 Toward Phase 2 Study of Edge Therapeutics’ Lead Compound to Improve Outcomes After Brain Injury
Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
Epratuzumab Results in Lupus Presented at 2012 Annual European Congress of Rheumatology
Top-line Data from Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Bristol-Myers Squibb Foundation Announces $6 Million in Grants to Develop Comprehensive Solutions for U.S. Adults with Diabetes and Announces $15 Million Expansion to China and India
June 7
Advaxis Completes Enrollment of Cohort 2 in Phase 2 CIN 2/3 Study
CRI Lifetree Presents Research Findings at the Annual NCDEU Meeting
Preclinical Research with Proteonomix’s UMK-121 Featured in Oral Presentation at the International Society for Cellular Therapy 18th Annual Meeting
Arno Therapeutics Announces Additional Orphan-Drug Designations for AR-42 in Europe
Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
June 6
ORENCIA® (abatacept) Demonstrates Comparable Efficacy to Humira® (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
Antares Pharma Announces Move to the NASDAQ Stock Market
The Medicines Company Prices $225 Million of Convertible Notes
Celgene Advances ABRAXANE® (nab-paclitaxel) Development in Difficult-to-Treat Cancers
June 5
Celator® Pharmaceuticals Announces Presentations of Positive Survival Analyses from CPX-351 Studies at ASCO Annual Meeting
June 4
Cyclacel Presents Phase 1 Data of Sequential Sapacitabine and Seliciclib in Advanced Solid Tumors at ASCO Annual Meeting
Senesco Provides SNS01-T Update on Phase 1b/2a Multiple Myeloma Trial
Immunomedics Reports Final Survival Data from Two-Part Pancreatic Cancer Study with Yttrium-90-Labeled Clivatuzumab Tetraxetan Combined With Gemcitabine
Unigene Enters Agreement to Eliminate 1/3 of Its Outstanding $67mm Debt
Data Evaluating Clinical Potential of ABRAXANE®(Nab-Paclitaxel) in Combination with Gemcitabine in Resectable Pancreatic Cancer Presented at ASCO
Aegerion Pharmaceuticals to Webcast Investor Event: Challenges and Opportunities in HoFH
Amicus Therapeutics to Participate in Three June Conferences
Cees Heiman Joins The Medicines Company to Lead Europe and Middle East Business
Data Evaluating Clinical Potential of ABRAXANE® (Nab-Paclitaxel) in Combination with Gemcitabine in Resectable Pancreatic Cancer Presented at ASCO
Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions of the BENEFIT and BENEFIT-EXT Clinical Trials of NULOJIX® (belatacept)
Enzon Presents Final Analysis of Phase II PEG-SN38 (EZN-2208) Study in Patients with Metastatic Breast Cancer at 2012 ASCO Meeting
June 3
Advaxis to Report Updated Safety, Tumor Response, and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer at ASCO
June 2
Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1 Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer
Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2) in Patients with Recurrent Follicular Lymphoma Presented at ASCO
Multiple Analyses Evaluating ABRAXANE® (Nab-Paclitaxel) in Non-Small Cell Lung Cancer Presented at ASCO
June 1
NPS Pharmaceuticals Joins the Hypoparathyroidism Association in Recognition of World Hypoparathyroidism Awareness Day
Onconova Presents Clinical Trial Data for Oral Rigosertib at ASCO Annual Meeting
Cyclacel Presents New Phase 2 Data of Sapacitabine for MDS at ASCO Annual Meeting
May 31
Celldex Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
Photocure Announces Positive Results of Phase 2b Study Evaluating Visonac® in Acne
Temptime Announces Business Expansion in Asia
Antares Pharma to Present at the Jefferies Global Healthcare Conference
Pre-Clinical Data Demonstrates Promising Potential of MannKind’s IRE1a Inhibitor to Treat Multiple Myeloma
May 30
Lexicon Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Senesco’s SNS01-T to Be Presented during Poster Session at 2012 Annual Meeting of the American Society of Clinical Oncology
Aegerion Pharmaceuticals Announces Participation at Jefferies 2012 Global Healthcare Conference
May 29
Advaxis Completes Enrollment in Phase 2 Cervical Cancer Study
Bristol-Myers Squibb Announces Global Collaboration with Leading Academic Institutions to Advance Science of Immuno-Oncology
Immunomedics to Present at Jefferies 2012 Global Healthcare Conference
Online Database of Pharmacovigilance Requirements in over 75 countries on All Continents (GRID™) Launched by Pharmaceutical Regulatory Services, Inc.
NPS Pharmaceuticals to Present at Jefferies Global Healthcare Conference
Aegerion Pharmaceuticals Announces Oral Presentation of Phase III Lomitapide Data at European Atherosclerosis Society Conference
May 25
Immunomedics to Present Final Results of Pancreatic Cancer Study with Clivatuzumab at 2012 Annual Meeting of the American Society of Clinical Oncology
May 24
CEO Bob Bradway Takes the Helm at Amgen
BIO Statement on New Bill to Extend Therapeutic Discovery Project Tax Credit
May 23
Celldex Therapeutics to Host Call to Announce Topline Results from the EMERGE Study in Advanced Breast Cancer
The Avoca Group Holds Quality Summit to Debate Adoption of Quality Standards
IBM Watson, Brain Machine Interfaces, and Synthetic Biology Take Center Stage in May Issue of IEEE Life Sciences Newsletter
May 22
Unigene’s Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Celgene Corporation to Present at Sanford C. Bernstein’s 28th Annual Strategic Decisions Conference
Merck Announces Third-Quarter 2012 Dividend
May 21
Digestive Disease Week Presentations Support Therapeutic Potential for Gattex (teduglutide) as Novel Treatment for Adult Short Bowel Syndrome
Unigene to Present at TIDES 2012
FDA Approves New Labeling for ISENTRESS® (raltegravir) to Include 156-Week Data Demonstrating Long-Term Efficacy, Safety and Tolerability with ISENTRESS in Combination Therapy in Previously Untreated Adult Patients Infected with HIV-1
Amicus Therapeutics Added to NASDAQ Biotechnology Index
Dendreon Announces Data Presentation at the 2012 American Urological Association Annual Meeting
May 18
Celldex Therapeutics to Host Call to Announce Topline Results from the EMERGE Study in Advanced Breast Cancer
May 17
Cyclacel to Report New Sapacitabine Clinical Data at the American Society of Clinical Oncology Annual Meeting
May 16
STENTYS Self-Apposing® Stent Shows Very Low Mortality at One Month in 1,000 High-Risk Heart Attack Patients
New Data from Bristol-Myers Squibb Oncology Portfolio to be Presented at 2012 American Society of Clinical Oncology (ASCO) Annual Meeting
